Professor Joop Ter Horst

Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

Joop ter Horst leads an application driven fundamental research group that will facilitate the paradigm shift to continuous manufacturing in the pharmaceutical industry. The group will identify routes to exploit the fundamental principles relating molecule, crystal structure and crystallization process phenomena to the crystal product quality to come to hybrid separation technologies to be incorporated in the continuous pharmaceutical manufacturing chain. He adopts a view from the molecular level and up for gaining fundamental understanding to use in control and prediction of new industrial crystallization processes. He cooperates with many university groups inside and outside the UK and his research benefits many industrial partners. 

Publications

Enabling precision manufacturing of active pharmaceutical ingredients : workflow for seeded cooling continuous crystallisation
Brown Cameron J, McGlone Thomas, Yerdelen Stephanie, Srirambhatla Vijay, Mabbott Fraser, Gurung Rajesh, Briuglia Maria L, Ahmed Bilal, Polyzois Hector, McGinty John, Perciballi Francesca, Fysikopoulos Dimitris, Macfhionnghaile Pól, Siddique Humera, Raval Vishal, Harrington Tomás S, Vassileiou Antony, Robertson Murray, Prasad Elke, Johnston Andrea, Johnston Blair, Nordon Alison, Srai Jagjit, Halbert Gavin, Ter Horst Joop H, Price Chris J, Rielly Chris D, Sefcik Jan, Florence Alastair J
Molecular Systems Design & Engineering Vol 2018, pp. 518-549 (2018)
https://doi.org/10.1039/C7ME00096K
Enabling precision manufacturing of active pharmaceutical ingredients : workflow for seeded cooling continuous crystallisations
Brown Cameron J, McGlone Thomas, Yerdelen Stephanie, Srirambhatla Vijay, Mabbott Fraser, Gurung Rajesh, Briuglia Maria L, Ahmed Bilal, Polyzois Hector, Mcginty John, Perciballi Francesca, Fysikopoulos Dimitris, Macfhionnghaile Pól, Siddique Humera, Raval Vishal, Harrington Tomás S, Vassileiou Antony D, Robertson Murray, Prasad Elke, Johnston Andrea, Johnston Blair, Nordon Alison, Srai Jagjit S, Halbert Gavin, ter Horst Joop H, Price Chris J, Rielly Chris D, Sefcik Jan, Florence Alastair J
Molecular Systems Design and Engineering Vol 3, pp. 518-549 (2018)
https://doi.org/10.1039/c7me00096k
Particle breakage kinetics and mechanisms in attrition-enhanced deracemization
Xiouras Christos, Fytopoulos Antonios A, Ter Horst Joop H, Boudouvis Andreas G, Van Gerven Tom, Stefanidis Georgios D
Crystal Growth and Design Vol 18, pp. 3051-3061 (2018)
https://doi.org/10.1021/acs.cgd.8b00201
Scaling up temperature cycling-induced deracemization by suppressing nonstereoselective processes
Steendam René R E, ter Horst Joop H
Crystal Growth and Design Vol 18, pp. 3008-3015 (2018)
https://doi.org/10.1021/acs.cgd.8b00121
Particle size distributions and performance of preferential crystallization of L-asparagine·H2O with tailor-made additives
Kongsamai Peetikamol, Flood Chalongsri, ter Horst Joop H, Flood Adrian E
Chemical Engineering and Technology (2018)
https://doi.org/10.1002/ceat.201700668
Rapid and scale-independent microfluidic manufacture of liposomes entrapping protein incorporating in-line purification and at-line size monitoring
Forbes Neil, Hussain Maryam T, Briuglia Maria L, Edwards Darren P, ter Horst Joop H, Szita Nicolas, Perrie Yvonne
International Journal of Pharmaceutics Vol 556, pp. 68-81 (2018)
https://doi.org/10.1016/j.ijpharm.2018.11.060

more publications

Professional activities

Tutorial Industrial Crystallization Fundamentals
Speaker
3/9/2017
Crystal Nucleation in Complex Multicomponent Solutions
Speaker
12/9/2017
biwic 2017
Participant
29/8/2017
External Examiner for the PhD student Sharlinda Salim Sachithananthan in the Group of Prof. Sven Schroeder, Leeds University
Examiner
23/8/2017
Lina Harfouche
Host
21/8/2017
Giuseppe Belletti
Host
21/8/2017

more professional activities

Projects

to develop a workflow for the rapid measurement of phase diagrams for multicomponent systems student placement Olayinka Olalere
Ter Horst, Joop (Principal Investigator)
01-Jan-2018 - 31-Jan-2019
Doctoral Training Partnership (DTP 2016-2017 University of Strathclyde) | Walsh, Erin
Markl, Daniel (Principal Investigator) Ter Horst, Joop (Co-investigator) Walsh, Erin (Research Co-investigator)
01-Jan-2018 - 01-Jan-2021
CMAC Core project: Impurity Rejection
Florence, Alastair (Principal Investigator) Ter Horst, Joop (Co-investigator)
01-Jan-2017 - 30-Jan-2019
Future Continuous Manufacturing and Advanced Crystallisation Research Hub (CMAC Hub)
Florence, Alastair (Principal Investigator) Halbert, Gavin (Co-investigator) Johnston, Blair (Co-investigator) Nordon, Alison (Co-investigator) Price, Chris John (Co-investigator) Sefcik, Jan (Co-investigator) Ter Horst, Joop (Co-investigator)
"Our Hub research is driven by the societal need to produce medicines and materials for modern living through novel manufacturing processes. The enormous value of the industries manufacturing these high value products is estimated to generate £50 billion p.a. in the UK economy. To ensure international competitiveness for this huge UK industry we must urgently create new approaches for the rapid design of these systems, controlling how molecules self-assemble into small crystals, in order to best formulate and deliver these for patient and customer. We must also develop the engineering tools, process operations and control methods to manufacture these products in a resource-efficient way, while delivering the highest quality materials. Changing the way in which these materials are made, from what is called batch crystallisation (using large volume tanks) to continuous crystallisation (a more dynamic, flowing process), gives many advantages, including smaller facilities, more efficient use of expensive ingredients such as solvents, reducing energy requirements, capital investment, working capital, minimising risk and variation and, crucially, improving control over the quality and performance of the particles making them more suitable for formulation into final products. The vision is to quickly and reliably design a process to manufacture a given material into the ideal particle using an efficient continuous process, and ensure its effective delivery to the consumer. This will bring precision medicines and other highly customisable projects to market more quickly. An exemplar is the hubs exciting innovation partnership with Cancer Research UK. Our research will develop robust design procedures for rapid development of new particulate products and innovative processes, integrate crystallisation and formulation to eliminate processing steps and develop reconfiguration strategies for flexible production. This will accelerate innovation towards redistributed anufacturing, more personalisation of products, and manufacturing closer to the patient/customer. We will develop a modular MicroFactory for integrated particle engineering, coupled with a fully integrated, computer-modelling approach to guide the design of processes and materials at molecule, particle and formulation levels. This will help optimise what we call the patient-centric supply chain and provide customisable products. We will make greater use of targeted experimental design, prediction and advanced computer simulation of new formulated materials, to control and optimise the processes to manufacture them. Our talented team of scientists will use the outstanding capabilities in the award winning £34m CMAC National Facility at Strathclyde and across our 6 leading university spokes (Bath, Cambridge, Imperial, Leeds, Loughborough, Sheffield). This builds on existing foundations independently recognised by global industry as 'exemplary collaboration between industry, academia and government which represents the future of pharmaceutical manufacturing and supply chain framework'. Our vision will be translated from research into industry through partnership and co-investment of £31m. This includes 10 of world's largest pharmaceutical companies (eg AstraZeneca, GSK), chemicals and food companies (Syngenta, Croda, Mars) and 19 key technology companies (Siemens, 15 SMEs) Together, with innovation spokes eg Catapult (CPI) we aim to provide the UK with the most advanced, integrated capabilities to deliver continuous manufacture, leading to better materials, better value, more sustainable and flexible processes and better health and well-being for the people of the UK and worldwide. CMAC will create future competitive advantage for the UK in medicines manufacturing and chemicals sector and is strongly supported by industry / government bodies, positioning the UK as the investment location choice for future investments in research and manufacturing."
01-Jan-2017 - 31-Jan-2023
Scale-Up and Continuos Viedma Ripening
Steendam, Rienk (Co-investigator) ter Keurst, Marc (Research Co-investigator) Ter Horst, Joop (Principal Investigator)
Viedma ripening involves the transformation of a racemic mixture of chiral crystals into one chiral form. Attempts were made to scale-up this process but failed. In this project the reason for the failed scale-up attempts will be investigated. Scale-up and continuous Viedma ripening will be attempted in a different manner using different setups, compounds and different crystal size distributions.
07-Jan-2016 - 12-Jan-2017
Doctoral Training Partnership (DTP 2016-2017 University of Strathclyde) | Moreno Leon, Carlos
Ter Horst, Joop (Principal Investigator) Roy, Sudipta (Co-investigator) Moreno Leon, Carlos (Research Co-investigator)
01-Jan-2016 - 01-Jan-2020

more projects

Address

Strathclyde Institute of Pharmacy and Biomedical Sciences
Technology Innovation Centre

Location Map

View University of Strathclyde in a larger map